Cabiralizumab

• CAT Number: I042444
• CAS Number: 1613144-80-1
• Purity: ≥95%

Cabiralizumab (Cat No.: I042444) is a humanized monoclonal antibody that targets colony-stimulating factor-1 receptor (CSF1R), a key regulator of macrophage differentiation and survival. By inhibiting CSF1R signaling, Cabiralizumab depletes immunosuppressive tumor-associated macrophages (TAMs), enhancing anti-tumor immune responses. It has been investigated in combination with immune checkpoint inhibitors for treating solid tumors, including pancreatic and non-small cell lung cancers. Cabiralizumab represents a novel immuno-oncology strategy aimed at remodeling the tumor microenvironment and overcoming resistance to conventional cancer immunotherapies.

Reference

[1]. Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767.
[Content Brief]

[2]. Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70.
[Content Brief]